These studies led Hahn et al. (1999) to hypothesize that “changes in PKC may be an illness-specific marker” for bipolar disorder, with enhanced PKC activity during mania being suppressed following mood-stabilizer treatment as manic symptoms improve (Hahn and Friedman, 1999). The gene discussed is PRRT2; the disease is bipolar disorder.